Business
TPT Global Tech's Medical Division Completes Manufactuing of the First of its Kind "Quiklab" a Mobile Turnkey Covid 19 Testing and Monitoring Lab
TPT Global Tech's Medical Division Completes Manufactuing of the First of its Kind "Quiklab" a Mobile Turnkey Covid 19 Testing and Monitoring Lab.
About this update from Tpt Global Tech, Inc.
[{"type":"text","content":"Our Quiklab Use Case utilizes and showcases all of TPT Global Tech's technology platforms strengths (Telecom, Media, SaaS, Medical and Smartphone) in a single business model pushing TPT Global Tech, we believe, to the forefront in the fight against Covid 19 testing and beyond.SAN DIEGO, CA / ACCESSWIRE / June 18, 2020 / TPT Global Tech, Inc. ("TPTW, the Company or TPT Global Tech") (OTCBB:TPTW) announced today with the completion of a recent manufacturing acquisition "Aire Fitness" the Company's Medical Division, "TPT MedTech" has completed the manufacturing of what it believes is the first of its kind Mobile Turnkey Covid 19 Testing and Monitoring lab "Quiklab".TPT MedTech has developed an approach which utilizes "Quiklab", a two-phase solution coupled to a PPE product distribution model. The PPE distribution model is focused in the Federal space (VA/DoD/FEMA/CDC/NG) as well as the top 20 National Hospital Group Purchasing Organizations (GPO).TPT MedTech "Quiklab" developed a sequenced cohesive solution designed to address the risk of contracting COVID-19 inadvertently through touch or aerosolized. TPT MedTech "Quiklab" created this safety barrier with a two-phase independent Mobile Lab System. QUIKLAB CLEANSER Lab initially scans for fever, you enter lab and stand for 15 seconds while a fog (FDA APPROVED) eliminates 99.9% of topical viruses and bacteria. Upon completion the individual enters the QUIKLAB TESTING Lab for a mucosal swab. (13-15 min). This eliminates any individual who is COVID-19 active or appears symptom free. The QUIKLAB CLEANSER has significant applications well beyond just medical.The point-of-care diagnostics or testing (POCD or POCT) marketplace is projected to reach 46.7 billion USD by 2024 from 28.5 billion USD in 2019, at a CAGR of 10.4%. Factors such as the high prevalence of infectious diseases in developing countries, increasing incidence of target conditions, growing government support, and rising preference for home healthcare across the globe are driving the growth of the market.The rapid turnaround times, improved decision times, and time-critical decision-making of TPT MedTech "Quiklab" can result in total savings between 8-20% of laboratory costs for facilities that implement POC testing. The savings realized...